Demcizumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameDemcizumab
Drug Alias Name登西组单抗Anti-DLL4 monoclonal antibody (OncoMed)Anti-delta-like ligand 4 monoclonal antibody (OncoMed)登赛珠单抗Demcizumabum +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionDelta-like protein 4 inhibitors
TargetsDelta-like protein 4
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOncomed Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOncomed Pharmaceuticals IncCelgene Corp
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG